SCHEMBL6442633

SCHEMBL6442633

N#Cc1c(NCc2ccc(S(N)(=O)=O)cc2)nc(N)nc1-c1ccco1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 5/20 0.50
CA2 P00918 5/20 0.50
CA13 Q8N1Q1 3/20 0.50
CA7 P43166 2/20 0.50
ADORA2A P29274 10/20 0.49
ADORA1 P30542 8/20 0.49
ADORA2B P29275 5/20 0.49
ADORA3 P0DMS8 3/20 0.49
CA9 Q16790 2/20 0.48
KDM4E B2RXH2 3/20 0.44
ALDH1A1 P00352 3/20 0.44
HPGD P15428 3/20 0.44
LMNA P02545 1/20 0.44
POLB P06746 1/20 0.44
SMARCA2 P51531 1/20 0.44
MAPK8 P45983 1/20 0.41
MAPK9 P45984 1/20 0.41
GAA P10253 2/20 0.41
MEN1 O00255 1/20 0.41
GLA P06280 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6441989 0.91 MAPK8 (0.51) ADORA2AADORA1ADORA2BKDM4EALDH1A1
SCHEMBL5039795 0.87 ADORA2A (0.55) ADORA2AADORA1ADORA2BADORA3KDM4E
SCHEMBL5040171 0.86 ADORA2A (0.62) ADORA2AADORA1ADORA2BADORA3KDM4E
SCHEMBL5046823 0.85 ADORA2A (0.53) ADORA2AADORA1ADORA2BADORA3KDM4E
SCHEMBL5131303 0.85 ADORA2A (0.53) ADORA2AADORA1ADORA2BADORA3KDM4E
SCHEMBL5037033 0.85 KDM4E (0.53) ADORA2AADORA1ADORA2BADORA3KDM4E
SCHEMBL5040159 0.83 ADORA2A (0.50) ADORA2AADORA1ADORA2BADORA3KDM4E
SCHEMBL5046642 0.83 ADORA2A (0.50) ADORA2AADORA1ADORA2BADORA3KDM4E
SCHEMBL6441752 0.83 TP53 (0.51) ADORA2AADORA1ADORA2BADORA3KDM4E
SCHEMBL5040090 0.83 ADORA2A (0.50) ADORA2AADORA1ADORA2BADORA3KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1261327-B1 ADENOSINE RECEPTOR MODULATORS HOFFMANN LA ROCHE (CH) 2005-04-27 EP disclosed
US-6586441-B2 2-Amino-6-benzylsulfanyl-4-thiophen-2-yl-pyridine-3,5-dicarbo -nitrile as an examplary preferred compound; Alzheimer's and Parkinson's diseases; neuroprotectors; schizophrenia, analgesics; anxiolytic agents; respiratory disorders HOFFMAN-LA ROCHE INC. 2003-07-01 US disclosed
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease F. HOFFMANN-LA ROCHE AG (CH) 2001-10-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease ADORA2A, ADORA2B, ADORA1 CA1 966/4885CA2 504/4885CA13 2448/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.